Cancer Research Career Enhancement and Related Activities With education as the fourth pillar of its overall mission to End Cancer, The University of Texas MD Anderson Cancer Center is an accredited, degree-granting institution with numerous efforts in education, training, and career development across the spectrum of cancer research and translation, the science of cancer prevention, and clinical practice. More than 1,700 faculty and 7,000 annually appointed trainees?from high school through research postdoctoral fellows and clinical residents, as well as a community of lifelong learners among our research and administrative staff?take part in a wide array of offerings sponsored by multiple educational stakeholders from across the institution. Our long-term objective is to establish MD Anderson as a model for education and training in cancer research for a diverse, multidisciplinary research workforce through dissemination of best practices and organization of innovative, evidence-based curricula designed for 21st- century team-based science and clinical practice. Overall, the uniquely broad and rich environment for clinical and research education and professional development at MD Anderson demands easy access to high-quality resources for its learners, as individuals and as groups; for instructors to develop useful and effective activities in synergy; and for support and evaluation of such programs. With this in mind, our 5-year goals include multiple innovative efforts across all CCSG programs in 4 emphasis areas: 1) recruitment coordinated among stakeholders with new approaches that emphasize inclusiveness of underrepresented research trainees and those with disabilities; 2) facilitating access to research education via improved alignment and increased impact; 3) support applications centralized for access by all programs; and 4) program evaluation services tailored for support and improvement of current and developing efforts to improve mentorship and career development. To achieve our long-term objectives for the MD Anderson Cancer Research Career Enhancement and Related Activities (CRCE), our continuous efforts and coordinating role across the institution in education and training are described by these overall aims:
Aim 1 : To recruit, train, and promote a demographically diverse pool of research scientists who span all stages of training and faculty appointment using multiple rigorous strategies to reach broad audiences;
Aim 2 : To provide innovative and evidence-based educational and professional development opportunities in a nurturing culture of shared learning that is attuned to the needs of trainees and faculty mentors;
and Aim 3 : To serve as a coordination and support hub for innovation in education/training, sharing best practices, monitoring research training needs, and program evaluation for MD Anderson researchers, including the community of training programs at MD Anderson.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997865
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10
Dang, Nam H; Ogura, Michinori; Castaigne, Sylvie et al. (2018) Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 182:583-586
Chahoud, Jad; Sui, Dawen; Erwin, William D et al. (2018) Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24:2304-2311
Andermann, Tessa M; Peled, Jonathan U; Ho, Christine et al. (2018) The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant 24:1322-1340
Tiwary, Shweta; Morales, John E; Kwiatkowski, Sam C et al. (2018) Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a. Sci Rep 8:8267
Chen, Han; Li, Chunyan; Peng, Xinxin et al. (2018) A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173:386-399.e12
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 12418 publications